Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 172

1.

Using ecological socioeconomic position (SEP) measures to deal with sample bias introduced by incomplete individual-level measures: inequalities in breast cancer stage at diagnosis as an example.

Lamy S, Molinié F, Daubisse-Marliac L, Cowppli-Bony A, Ayrault-Piault S, Fournier E, Woronoff AS, Delpierre C, Grosclaude P.

BMC Public Health. 2019 Jul 2;19(1):857. doi: 10.1186/s12889-019-7220-4.

2.

Multidisciplinary team meeting and EUSOMA quality indicators in breast cancer care: A French regional multicenter study.

Pons-Tostivint E, Daubisse-Marliac L, Grosclaude P, Oum Sack E, Goddard J, Morel C, Dunet C, Sibrac L, Lagadic C, Bauvin E, Bergé Y, Bernard-Marty C, Vaysse C, Lacaze JLL; EvaSein Group.

Breast. 2019 Aug;46:170-177. doi: 10.1016/j.breast.2019.06.001. Epub 2019 Jun 7.

PMID:
31226572
3.

Impact of comorbidity in DBLCL: direct and indirect effects on survival through unplanned chemotherapy dose reduction.

Lamy S, Laurent G, Lepage B, Grosclaude P, Delpierre C.

J Intern Med. 2019 Apr;285(4):472-474. doi: 10.1111/joim.12879. Epub 2019 Feb 15. No abstract available.

PMID:
30681214
4.

Are there variations in adherence to colorectal cancer clinical guidelines depending on treatment place and recommendation novelty? The French EvaCCoR observational study.

Lamy S, Guimbaud R, Digue L, Cirilo-Cassaigne I, Bousser V, Oum-Sack E, Goddard J, Bauvin E, Delpierre C, Grosclaude P; EvaCCoR Group.

Clin Res Hepatol Gastroenterol. 2019 Jun;43(3):346-356. doi: 10.1016/j.clinre.2018.10.008. Epub 2018 Nov 15.

PMID:
30447905
5.

Are comorbidities associated with long-term survival of lung cancer? A population-based cohort study from French cancer registries.

Seigneurin A, Delafosse P, Trétarre B, Woronoff AS, Velten M, Grosclaude P, Guizard AV, Lapôtre-Ledoux B, Bara S, Molinié F, Colonna M.

BMC Cancer. 2018 Nov 12;18(1):1091. doi: 10.1186/s12885-018-5000-7.

6.

Erratum to "Time trends and short term projections of cancer prevalence in France" [Cancer Epidemiol. 56 (2018) 97-105].

Colonna M, Boussari O, Cowppli-Bony A, Delafosse P, Romain G, Grosclaude P, Jooste V; French Network of Cancer Registries (FRANCIM).

Cancer Epidemiol. 2018 Dec;57:158-159. doi: 10.1016/j.canep.2018.10.001. Epub 2018 Oct 5. No abstract available.

PMID:
30293874
7.

Time trends and short term projections of cancer prevalence in France.

Colonna M, Boussari O, Cowppli-Bony A, Delafosse P, Romain G, Grosclaude P, Jooste V; French Network of Cancer Registries (FRANCIM).

Cancer Epidemiol. 2018 Oct;56:97-105. doi: 10.1016/j.canep.2018.08.001. Epub 2018 Aug 17. Erratum in: Cancer Epidemiol. 2018 Dec;57:158-159.

PMID:
30125884
8.

A novel approach for medical research on lymphomas: A study validation of claims-based algorithms to identify incident cases.

Conte C, Palmaro A, Grosclaude P, Daubisse-Marliac L, Despas F, Lapeyre-Mestre M.

Medicine (Baltimore). 2018 Jan;97(2):e9418. doi: 10.1097/MD.0000000000009418.

9.

Merkel cell carcinoma in France: a registries-based, comprehensive epidemiological survey.

Fondain M, Dereure O, Uhry Z, Guizard AV, Woronoff AS, Colonna M, Molinie F, Bara S, Velten M, Marrer E, Grosclaude P, Lapôtre-Ledoux B, Tretarre B, Guillot B.

J Eur Acad Dermatol Venereol. 2018 Aug;32(8):1292-1296. doi: 10.1111/jdv.14798. Epub 2018 Mar 9.

PMID:
29341266
10.

Disentangling the influence of living place and socioeconomic position on health services use among diabetes patients: A population-based study.

Lamy S, Ducros D, Diméglio C, Colineaux H, Fantin R, Berger E, Grosclaude P, Delpierre C, Bouhanick B.

PLoS One. 2017 Nov 29;12(11):e0188295. doi: 10.1371/journal.pone.0188295. eCollection 2017.

11.

Long-term trends in incidence and survival of penile cancer in France.

Daubisse-Marliac L, Colonna M, Trétarre B, Defossez G, Molinié F, Jéhannin-Ligier K, Marrer E; FRANCIM network, Grosclaude P.

Cancer Epidemiol. 2017 Oct;50(Pt A):125-131. doi: 10.1016/j.canep.2017.08.014. Epub 2017 Sep 9.

PMID:
28898817
12.

Survival of solid cancer patients in France, 1989-2013: a population-based study.

Cowppli-Bony A, Uhry Z, Remontet L, Voirin N, Guizard AV, Trétarre B, Bouvier AM, Colonna M, Bossard N, Woronoff AS, Grosclaude P; French Network of Cancer Registries (FRANCIM).

Eur J Cancer Prev. 2017 Nov;26(6):461-468. doi: 10.1097/CEJ.0000000000000372.

PMID:
28598889
13.

Oral cancer characteristics in France: Descriptive epidemiology for early detection.

Jéhannin-Ligier K, Dejardin O, Lapôtre-Ledoux B, Bara S, Coureau G, Grosclaude P, Marrer E, Molinié F, Trétarre B, Velten M, Woronoff AS, Colonna M, Guizard AV.

J Stomatol Oral Maxillofac Surg. 2017 Apr;118(2):84-89. doi: 10.1016/j.jormas.2017.02.003. Epub 2017 Feb 24.

PMID:
28330788
14.

Identifying multiple myeloma patients using data from the French health insurance databases: Validation using a cancer registry.

Palmaro A, Gauthier M, Conte C, Grosclaude P, Despas F, Lapeyre-Mestre M.

Medicine (Baltimore). 2017 Mar;96(12):e6189. doi: 10.1097/MD.0000000000006189.

15.

[Prostate cancer: Quality assessment of clinical management in the Midi-Pyrenean region in 2011].

Daubisse-Marliac L, Lamy S, Lunardi P, Tollon C, Thoulouzan M, Latorzeff I, Bauvin E, Grosclaude P; Evacap-Oncomip.

Prog Urol. 2017 Feb;27(2):68-79. doi: 10.1016/j.purol.2016.12.007. Epub 2017 Jan 20. French.

PMID:
28117234
16.

Assessment of the ecological bias of seven aggregate social deprivation indices.

Bryere J, Pornet C, Copin N, Launay L, Gusto G, Grosclaude P, Delpierre C, Lang T, Lantieri O, Dejardin O, Launoy G.

BMC Public Health. 2017 Jan 17;17(1):86. doi: 10.1186/s12889-016-4007-8.

17.

Trends in net survival from prostate cancer in six European Latin countries: results from the SUDCAN population-based study.

Grosclaude P, Roche L, Fuentes-Raspall R, Larrañaga N; GRELL EUROCARE-5 Working Group.

Eur J Cancer Prev. 2017 Jan;26 Trends in cancer net survival in six European Latin Countries: the SUDCAN study:S114-S120. doi: 10.1097/CEJ.0000000000000304.

PMID:
28005614
18.

Socioeconomic status and site-specific cancer incidence, a Bayesian approach in a French Cancer Registries Network study.

Bryere J, Dejardin O, Launay L, Colonna M, Grosclaude P, Launoy G; French Network of Cancer Registries (FRANCIM).

Eur J Cancer Prev. 2018 Jul;27(4):391-398. doi: 10.1097/CEJ.0000000000000326.

PMID:
27879493
19.

The care center influences the management of lymphoma patients in a universal health care system: an observational cohort study.

Lamy S, Bettiol C, Grosclaude P, Compaci G, Albertus G, Récher C, Nogaro JC, Despas F, Laurent G, Delpierre C.

BMC Health Serv Res. 2016 Aug 2;16(a):336. doi: 10.1186/s12913-016-1553-9.

20.

Current impact of age and comorbidity assessment on prostate cancer treatment choice and over/undertreatment risk.

Lunardi P, Ploussard G, Grosclaude P, Roumiguié M, Soulié M, Beauval JB, Malavaud B.

World J Urol. 2017 Apr;35(4):587-593. doi: 10.1007/s00345-016-1900-9. Epub 2016 Jul 21.

PMID:
27443847
21.

Are disparities of waiting times for breast cancer care related to socio-economic factors? A regional population-based study (France).

Ayrault-Piault S, Grosclaude P, Daubisse-Marliac L, Pascal J, Leux C, Fournier E, Tagri AD, Métais M, Lombrail P, Woronoff AS, Molinié F.

Int J Cancer. 2016 Nov 1;139(9):1983-93. doi: 10.1002/ijc.30266. Epub 2016 Aug 2.

22.

Risk of second primary cancer after a first potentially-human papillomavirus-related cancer: A population-based study.

Neumann F, Jégu J, Mougin C, Prétet JL, Guizard AV, Lapôtre-Ledoux B, Bara S, Bouvier V, Colonna M, Troussard X, Trétarre B, Grosclaude P, Velten M, Woronoff AS.

Prev Med. 2016 Sep;90:52-8. doi: 10.1016/j.ypmed.2016.06.041. Epub 2016 Jun 28.

PMID:
27370167
23.

Long-term quality of life among localised prostate cancer survivors: QALIPRO population-based study.

Kerleau C, Guizard AV, Daubisse-Marliac L, Heutte N, Mercier M, Grosclaude P, Joly F; French Network of Cancer Registries (FRANCIM).

Eur J Cancer. 2016 Aug;63:143-53. doi: 10.1016/j.ejca.2016.05.020. Epub 2016 Jun 15.

PMID:
27318002
24.

Enabling the transferability of complex interventions: exploring the combination of an intervention's key functions and implementation.

Villeval M, Bidault E, Shoveller J, Alias F, Basson JC, Frasse C, Génolini JP, Pons E, Verbiguié D, Grosclaude P, Lang T.

Int J Public Health. 2016 Dec;61(9):1031-1038. Epub 2016 Apr 11.

PMID:
27063950
25.

[An intervention research program (AAPRISS) to reduce social inequalities in health: methods and validation].

Villeval M, Bidault E, Gaborit E, Grosclaude P, Haschar-Noé N, Lang T; groupe AAPRISS.

Can J Public Health. 2015 Oct 3;106(6):e434-41. doi: 10.17269/cjph.106.4955. French.

PMID:
26680436
26.

Primary care physicians and oncologists are partners in cancer announcement.

Rougé Bugat ME, Omnes C, Delpierre C, Escourrou E, Boussier N, Oustric S, Delord JP, Bauvin E, Grosclaude P.

Support Care Cancer. 2016 Jun;24(6):2473-9. doi: 10.1007/s00520-015-3049-2. Epub 2015 Dec 14.

PMID:
26667626
27.

Sur-traitement et sous traitement du cancer de la prostate en Midi-Pyrénées.

Lunardi P, Beauval J, Gamé X, Roumiguié M, Thoulouzan M, Doumerc N, Huyghe E, Soulié M, Rischmann P, Grosclaude P, Malavaud B.

Prog Urol. 2015 Nov;25(13):756. doi: 10.1016/j.purol.2015.08.083. French. No abstract available.

PMID:
26544279
28.

Âge, comorbidités et cancer de la prostate : où en est-on du sur-diagnostic en Midi-Pyrénées ?

Lunardi P, Beauval J, Gamé X, Roumiguié M, Thoulouzan M, Doumerc N, Huyghe E, Soulié M, Rischmann P, Grosclaude P, Malavaud B.

Prog Urol. 2015 Nov;25(13):755-6. doi: 10.1016/j.purol.2015.08.082. French. No abstract available.

PMID:
26544276
29.

Trends in the risk of second primary cancer among bladder cancer survivors: a population-based cohort of 10 047 patients.

Muller J, Grosclaude P, Lapôtre-Ledoux B, Woronoff AS, Guizard AV, Bara S, Colonna M, Troussard X, Bouvier V, Trétarre B, Velten M, Jégu J.

BJU Int. 2016 Jul;118(1):53-9. doi: 10.1111/bju.13351. Epub 2015 Nov 17.

30.

[Use of medical and administrative databases to measure social health inequalities].

Ducros D, Nicoules V, Chehoud H, Bayle A, Souche A, Tanguy M, Valière JP, Cayla F, Grosclaude P.

Sante Publique. 2015 May-Jun;27(3):383-94. French. Erratum in: Sante Publique. 2015 Jul-Aug;27(4):609.

PMID:
26414140
31.

Ovarian cancer in France: trends in incidence, mortality and survival, 1980-2012.

Trétarre B, Molinié F, Woronoff AS, Bossard N, Bessaoud F, Marrer E, Grosclaude P, Guizard AV, Delafosse P, Bara S, Velten M, Lapôtre-Ledoux B, Ligier K, Léone N, Arveux P, Uhry Z.

Gynecol Oncol. 2015 Nov;139(2):324-9. doi: 10.1016/j.ygyno.2015.09.013. Epub 2015 Sep 14.

PMID:
26383829
32.

Cancer Risk in Women Exposed to Diethylstilbestrol in Utero.

Tournaire M, Devouche E, Espié M, Asselain B, Levadou A, Cabau A, Dunbavand A, Grosclaude P, Epelboin S.

Therapie. 2015 Sep-Oct;70(5):433-41. doi: 10.2515/therapie/2015030. Epub 2015 Jun 12.

PMID:
26071143
33.

[Prostate cancer incidence and mortality trends in France from 1980 to 2011].

Grosclaude P, Belot A, Daubisse Marliac L, Remontet L, Leone N, Bossard N, Velten M; réseau Francim.

Prog Urol. 2015 Jul;25(9):536-42. doi: 10.1016/j.purol.2015.04.011. Epub 2015 Jun 1. French.

PMID:
26043950
34.

Recent trends in incidence, geographical distribution, and survival of papillary thyroid cancer in France.

Colonna M, Uhry Z, Guizard AV, Delafosse P, Schvartz C, Belot A, Grosclaude P; FRANCIM network.

Cancer Epidemiol. 2015 Aug;39(4):511-8. doi: 10.1016/j.canep.2015.04.015. Epub 2015 May 21.

PMID:
26003877
35.

Total and partial cancer prevalence in the adult French population in 2008.

Colonna M, Mitton N, Bossard N, Belot A, Grosclaude P; French Network of Cancer Registries (FRANCIM).

BMC Cancer. 2015 Mar 19;15:153. doi: 10.1186/s12885-015-1168-2.

36.

Guideline sheets on the side effects of anticancer drugs are useful for general practitioners.

Rouge-Bugat ME, Lassoued D, Bacrie J, Boussier N, Delord JP, Oustric S, Bauvin E, Lapeyre-Mestre M, Bertucci F, Grosclaude P.

Support Care Cancer. 2015 Dec;23(12):3473-80. doi: 10.1007/s00520-015-2705-x. Epub 2015 Mar 27.

PMID:
25814443
37.

A health equity impact assessment umbrella program (AAPRISS) to tackle social inequalities in health: program description.

Lang T, Bidault E, Villeval M, Alias F, Gandouet B, Servat M, Theis I, Breton E, Haschar-Noé N, Grosclaude P.

Glob Health Promot. 2016 Sep;23(3):54-62. doi: 10.1177/1757975914568127. Epub 2015 Mar 20.

PMID:
25795655
38.

[Interdisciplinarity in action: "trap-words" in interdisciplinary research].

Villeval M, Ginsbourger T, Bidault E, Alias F, Delpierre C, Gaborit E, Kelly-Irving M, Manuello P, Grosclaude P, Lang T; AAPRISS.

Sante Publique. 2014 Mar-Apr;26(2):155-63. French.

PMID:
25108956
39.

Guidelines for time-to-event end point definitions in sarcomas and gastrointestinal stromal tumors (GIST) trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†.

Bellera CA, Penel N, Ouali M, Bonvalot S, Casali PG, Nielsen OS, Delannes M, Litière S, Bonnetain F, Dabakuyo TS, Benjamin RS, Blay JY, Bui BN, Collin F, Delaney TF, Duffaud F, Filleron T, Fiore M, Gelderblom H, George S, Grimer R, Grosclaude P, Gronchi A, Haas R, Hohenberger P, Issels R, Italiano A, Jooste V, Krarup-Hansen A, Le Péchoux C, Mussi C, Oberlin O, Patel S, Piperno-Neumann S, Raut C, Ray-Coquard I, Rutkowski P, Schuetze S, Sleijfer S, Stoeckle E, Van Glabbeke M, Woll P, Gourgou-Bourgade S, Mathoulin-Pélissier S; Definition for the Assessment of Time-to-event Endpoints in Cancer Trials Initiative.

Ann Oncol. 2015 May;26(5):865-72. doi: 10.1093/annonc/mdu360. Epub 2014 Jul 28. Review.

40.

[Incidence and mortality of urological cancers in 2012 in France].

Rébillard X, Grosclaude P, Leone N, Velten M, Coureau G, Villers A, Irani J, Lebret T, Rigaud J, Pfister C, Patard JJ, Richaud P, Salomon L, Coloby P, Soulié M; Les membres du CCAFU.

Prog Urol. 2013 Nov;23 Suppl 2:S57-65. doi: 10.1016/S1166-7087(13)70047-2. French.

PMID:
24485294
41.

Adherence to consensus-based diagnosis and treatment guidelines in adult soft-tissue sarcoma patients: a French prospective population-based study.

Mathoulin-Pélissier S, Chevreau C, Bellera C, Bauvin E, Savès M, Grosclaude P, Albert S, Goddard J, Le Guellec S, Delannes M, Bui BN, Mendiboure J, Stoeckle E, Coindre JM, Kantor G, Kind M, Cowppli-Bony A, Hoppe S, Italiano A.

Ann Oncol. 2014 Jan;25(1):225-31. doi: 10.1093/annonc/mdt407. Epub 2013 Nov 26.

42.

Childhood adversity as a risk for cancer: findings from the 1958 British birth cohort study.

Kelly-Irving M, Lepage B, Dedieu D, Lacey R, Cable N, Bartley M, Blane D, Grosclaude P, Lang T, Delpierre C.

BMC Public Health. 2013 Aug 19;13:767. doi: 10.1186/1471-2458-13-767.

43.

Adverse childhood experiences and premature all-cause mortality.

Kelly-Irving M, Lepage B, Dedieu D, Bartley M, Blane D, Grosclaude P, Lang T, Delpierre C.

Eur J Epidemiol. 2013 Sep;28(9):721-34. doi: 10.1007/s10654-013-9832-9. Epub 2013 Jul 26.

44.

Consistency and inconsistency in testing biomarkers in breast cancer. A GRELL study in cut-off variability in the Romance language countries.

Crocetti E, Caldarella A, Ferretti S, Ardanaz E, Arveux P, Bara S, Barrios E, Bento MJ, Bordoni A, Buzzoni C, Candela G, Colombani F, Delafosse P, Federico M, Francart J, Giacomin A, Grosclaude P, Guizard AV, Izarzugaza I, Konzelmann I, La Rosa F, Lapotre B, Leone N, Ligier K, Mangone L, Marcos-Gragera R, Martinez R, Michelena MJ, Michiara M, Miranda A, Molinié F, Mugarza-Gomez C, Paci E, Piffer S, Puig-Vives M, Sacchettini C, Sánchez MJ, Traina A, Tretarre B, Tumino R, Van Vaerenbergh E, Velten M, Woronoff AS.

Breast. 2013 Aug;22(4):476-81. doi: 10.1016/j.breast.2013.04.012. Epub 2013 May 10.

PMID:
23669022
45.

Life expectancy estimates as a key factor in over-treatment: the case of prostate cancer.

Delpierre C, Lamy S, Kelly-Irving M, Molinié F, Velten M, Tretarre B, Woronoff AS, Buemi A, Lapôtre-Ledoux B, Bara S, Guizard AV, Colonna M, Grosclaude P.

Cancer Epidemiol. 2013 Aug;37(4):462-8. doi: 10.1016/j.canep.2013.03.014. Epub 2013 Apr 24.

PMID:
23623489
46.

Patterns of adjuvant chemotherapy for stage II and III colon cancer in France and Italy.

Bouvier AM, Minicozzi P, Grosclaude P, Bouvier V, Faivre J, Sant M.

Dig Liver Dis. 2013 Aug;45(8):687-91. doi: 10.1016/j.dld.2012.12.019. Epub 2013 Feb 19.

PMID:
23428703
47.

Cancer incidence and survival in adolescents and young adults in France, 2000-2008.

Desandes E, Lacour B, Belot A, Molinie F, Delafosse P, Tretarre B, Velten M, Sauleau EA, Woronoff AS, Guizard AV, Ganry O, Bara S, Grosclaude P, Troussard X, Bouvier V, Brugieres L, Clavel J.

Pediatr Hematol Oncol. 2013 May;30(4):291-306. doi: 10.3109/08880018.2012.762569. Epub 2013 Jan 30.

PMID:
23363314
48.

National cancer incidence is estimated using the incidence/mortality ratio in countries with local incidence data: is this estimation correct?

Uhry Z, Belot A, Colonna M, Bossard N, Rogel A, Iwaz J, Mitton N, Grosclaude P, Remontet L.

Cancer Epidemiol. 2013 Jun;37(3):270-7. doi: 10.1016/j.canep.2012.12.007. Epub 2013 Jan 9.

PMID:
23312453
49.

Cancer incidence estimation at a district level without a national registry: a validation study for 24 cancer sites using French health insurance and registry data.

Uhry Z, Remontet L, Colonna M, Belot A, Grosclaude P, Mitton N, Delacour-Billon S, Gentil J, Boussac-Zarebska M, Bossard N, Danzon A, Altana M, Frete F, Weill A, Rogel A.

Cancer Epidemiol. 2013 Apr;37(2):99-114. doi: 10.1016/j.canep.2012.10.010. Epub 2012 Nov 30.

PMID:
23200731
50.

[Compensable occupational disease and cancer: how to improve the recognition rate? "Cursus Laboris" Project in Midi-Pyrenees: feasibility study].

Rougé-Bugat ME, Hérin F, Julien S, Oustric S, Forichon E, Delaperche F, Bauvin E, Delord JP, Grosclaude P.

Bull Cancer. 2012 Oct;99(10):927-34. doi: 10.1684/bdc.2012.1649. French.

Supplemental Content

Loading ...
Support Center